Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $7.20 Analyst target: $16.40 Upside: 127.78%
Immatics NV, a clinical-stage biopharmaceutical company, focuses on the discovery and development of T-cell receptor (TCR) -based immunotherapies for the treatment of cancer in the United States. The company is headquartered in Tbingen, Germany.
See the full interactive analysis & chart →Informational only — not investment advice.